Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2025

Summary of Significant Accounting Policies

Summary of the items included within net loss regularly provided to the CODM

	Six months ended June 30,
	2025		2024
Revenue	$	38,717	$	32,694
Cost of revenue (excluding amortization of intangible assets)		11,910		10,095
Amortization of intangible assets		190		190
Gross profit		26,617		22,409
Sales and marketing:
Sales and sales management		22,830		22,421
International		2,808		2,426
Other sales and marketing (a)		7,827		9,372
Total sales and marketing		33,465		34,219
General and Administrative:
Finance and Legal		3,919		3,862
Other General and administrative (b)		4,043		3,588
Total general and administrative		7,962		7,450
Research and Development:
Clinical		1,780		2,136
Regulatory and quality		867		761
Other research and development (c)		2,096		1,819
Total research and development		4,743		4,716
Gain on sale of product line		—		7,580
Other segment items (d)		(1,634)		(1,865)
Net loss	$	(21,187)	$	(18,261)
(a) Other sales and marketing includes strategy, analytics and allocated facility expenses.
(b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses.
(c) Other research and development includes engineering and allocated facility expenses.
(d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, other income and income tax expense.

Schedule of reconciliation of all captions of cash, cash equivalents and restricted cash

	June 30,		June 30,
	2025		2024
Cash and cash equivalents	$	34,977	$	26,496
Restricted cash		265		265
Total cash and cash equivalents and restricted cash shown in statements of cash flows	$	35,242	$	26,761

Disaggregation of Revenue

The following table presents revenue disaggregated by the Company’s portfolio of products (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
OviTex	$	12,487	$	11,124	$	24,596	$	21,659
OviTex PRS		7,333		4,796		13,377		10,741
Other		377		171		744		294
Total revenue	$	20,197	$	16,091	$	38,717	$	32,694

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
June 30, 2025:
Cash equivalents – money market fund	$	33,035	$	—	$	—
December 31, 2024:
Cash equivalents – money market fund	$	48,131	$	—	$	—

Schedule of dilutive securities excluded

	Six months ended June 30,
	2025	2024
Stock options	2,817,979	2,239,140
Unvested restricted stock units	1,359,116	991,391
Common stock warrants	88,556	88,556
Total	4,265,651	3,319,087